SLC5A2 and type 1 diabetes mellitus: The safety and efficacy of SGLT2 inhibitors in the treatment of type 2 DM (T2DM) have been established in previous human studies (Haneda et al., 2016), and human studies are currently being conducted to explore their potential application in the treatment of type 1 DM (T1DM) (El Masri et al., 2018; Yamada et al., 2018).